Mid-sized M&A, collaborations, creative financing, and biotech consolidation will feature in 2023. IPOs and follow-ons play bit-parts.

From the Aduhelm approval to exuberant stock markets, life sciences investor and In Vivo Rising Leader John Cassidy shares insights into industry trends, highlighting areas where decisions may have moved away from scientific fundamentals.

Venture capital firm Arix is financing the Copenhangen, Denmark-based biotech, which is looking to play its part in the fast-maturing gene-editing field.

Private Company Edition: The average exit from biopharma investments rose from $356.8m in 2019 to $520.6m in 2020, explaining the staggering $12bn invested in the industry during the first half of this year versus $17bn for all of last year. In recent VC deals, VelosBio’s $137m series B was the largest.